The potential of TB treatment 8 weeks

Published Date: 08 Mar 2023

While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.

Read Full News

Latest News

Is AD Transmissible? The Evidence for ‘Iatrogenic’ Disease

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Signs India Distribution Deal for Takeda's Qdenga Dengue Vaccine

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

Screwworm Infests US Horse Before Port Reopens to Mexican Livestock

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

CDC Delay Holds Up Children's COVID Vaccine Orders, WSJ Reports

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

Exclusive-Pennsylvania Asks for CDC Measles Help Amid Kennedy Dispute

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

Older Adults Living With HIV: A New Focus on Healthy Aging

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Latest News

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

News All Time

Daily Probiotic Fails to Prevent Infections in Infants

Daily use of an oral probiotic from 6 to 24 months of age may not reduce the occurrence of ear or respiratory tract infections and antibiotic use in healthy infants.

Once-Monthly PrEP Drug Could Be Manufactured for $3 a Year

The current agreement manufacturer Merck has signed for global access to its once-monthly alimatravir would exclude countries with more than 230,000 new HIV acquisitions a year.

Testing for Duffy-Null Neutrophil Count Before Consult

By adding Duffy antigen testing to routine blood bank screens, VA identified 79 DANC patients, sparing many unnecessary bone marrow biopsies.

WHO Says Staff Shortage, Funding Challenges Hamper Congo Ebola Response

Shortages of trained staff, operational partners and funding are causing a bottleneck in efforts to expand the Ebola response in the Democratic Republic of Congo as the...

Lessons From Recent Viral Outbreaks

Despite advances in diagnostics and trial speeds, gaps in clinical care capacity, targeted therapies, and public communication threaten global preparedness for the next pandemic.

Cyclosporiasis Cases in Michigan Climb to Over 14,700, State Health Officials Say

Michigan health officials reported 14,718 cases linked to an outbreak of cyclosporiasis on Thursday, an increase ⁠of 208 cases since its last update a week...

Salmonella Outbreak Linked to Pumpkin Seeds Infects 81 in France

An outbreak of salmonella related to ⁠a batch of pumpkin seeds infected 81 people, ⁠hospitalising six, in several French regions between ⁠May and August, ‌the Health and...

As Schools Re-open, Congo Drops Remote Learning Plan in Ebola Red Zone

Schools reopened this week in areas of Democratic Republic of Congo hardest hit by Ebola, after authorities decided the risk of transmission ⁠was outweighed by the risk of...

WHO's Tedros Says Ebola Response Must Be Scaled Up to Tackle Congo Outbreak

The head of the World Health Organization on Wednesday said the Ebola response needs to be scaled up to tackle the outbreak in the Democratic Republic ⁠of Congo, with...

Gepotidacin as Effective as Standard Therapy for Gonorrhea

Nucleic acid amplification test-confirmed success rates for urogenital gonorrhea are high and similar to those of oral gepotidacin and ceftriaxone plus azithromycin, a phase 3 trial shows.

Health Officials Turn to Mobile-phone Data to Track Ebola Spread in Congo

Health officials battling the Ebola outbreak in eastern Democratic Republic of Congo are using anonymised mobile-phone data to map population movements and identify areas...

GSK to Advance MRNA Flu Vaccine to Late-stage Trial

(Corrects paragraph 4 to clarify that GSK plans to start more than 20, ⁠not 25, late-stage trials in 2026)

UK Pledges Additional £50 Million to Help Contain Ebola Outbreak in Congo

Britain said on Tuesday it would provide more than £50 ⁠million ($67.56 million) in new funding to support efforts to contain an ⁠Ebola outbreak in the Democratic Republic...

Congo's Ebola Outbreak Kills More Than 3,000, Government Figures Show

The number of deaths in Democratic Republic of Congo's Ebola outbreak has surpassed 3,000, government ⁠data showed on Wednesday, as the country's worst-ever epidemic...

USDA Cyclospora Research Projects Shelved Amid Funding Cuts and Relocations, Politico Reports

The Trump administration is shuttering two of the three U.S. Department of Agriculture research projects studying cyclospora, ⁠a foodborne parasite that has sickened...

Measles Cases in Pennsylvania Rise to 460 Amid Ongoing Outbreak

Pennsylvania's health department said on Friday the confirmed number of cases linked to a measles ⁠outbreak has reached 460 this year, an increase of 36 over its update two...

Recommended News For You

Scientists discover the 'roadmap' that aggressive cancer uses to spread

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

Could the Prostate Cancer Story of Francis Collins Dissuade Men from Active Surveillance?

Veterans of the Navy have high lung cancer rates associated with asbestos use.

mRNA-based COVID vaccines generate improved responses to immunotherapy

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

Recommended Articles For You

All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment 

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies 

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology 

Targeted Protein Degraders for Previously Undruggable Oncogenic Proteins 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

2.

Chronic pain and poor sleep are troublesome bed partners.

3.

Saturated Fat Tied to Worse Survival After Prostate Cancer

4.

Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer

5.

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

1.

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer

2.

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role

3.

Exposure Modeling for Bispecific Antibodies: Scientific Foundations and Clinical Implications

4.

Risk Assessment of Treatment-Related Liver Injury in Cancer Care

5.

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

How Advances in Cancer Research Are Improving Treatment Options

2.

Navigating the Complexities of Ph Negative ALL - Part III

3.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot